Showing 3,521 - 3,540 results of 3,563 for search '"antibody"', query time: 0.07s Refine Results
  1. 3521

    Metabolic reprogramming and macrophage expansion define ACPA-negative rheumatoid arthritis: insights from single-cell RNA sequencing by Yafeng Jiang, Zhaolan Hu, Roujie Huang, Kaying Ho, Pengfei Wang, Jin Kang, Jin Kang

    Published 2025-01-01
    “…BackgroundAnti-citrullinated peptide antibodies (ACPA)-negative (ACPA−) rheumatoid arthritis (RA) presents significant diagnostic and therapeutic challenges due to the absence of specific biomarkers, underscoring the need to elucidate its distinctive cellular and metabolic profiles for more targeted interventions.MethodsSingle-cell RNA sequencing data from peripheral blood mononuclear cells (PBMCs) and synovial tissues of patients with ACPA− and ACPA+ RA, as well as healthy controls, were analyzed. …”
    Get full text
    Article
  2. 3522

    INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses by Jason Ho, Chelsie Macedo, Garrett Cyprus, Rajay Pandit, Anya Polovina, Nadja Kern, Abrahim Hussain, Sae Jeong Ahn, William Crago, Emily Rowell, Florian J Sulzmaier, John C Timmer, Brendan P Eckelman

    Published 2023-01-01
    “…Recent engineering efforts, including non-α IL-2 variants, have lowered the toxicity profile, but have yet to induce meaningful antitumor activity in a wider patient population.Methods We engineered INBRX-120, a CD8α-targeted Cisleukin™ molecule consisting of an affinity tuned IL-2 (IL2-x) connected to two high affinity CD8α-specific single domain antibodies via an effector-silenced Fc domain. To show that this large affinity differential enables directed IL-2 cis-signaling exclusively on CD8α-expressing tumoricidal effector cell populations, INBRX-120 effects on target cell expansion, activation and antitumor activity were tested in vitro. …”
    Get full text
    Article
  3. 3523

    Medication underuse in real-life practice: the impact of galcanezumab towards achieving very low frequency episodic migraine in a southeast Asian middle-income nation by Wanakorn Rattanawong, Prakit Anukoolwittaya, Akarin Hiransuthikul, Thanakit Pongpitakmetha, Auranee Trisataya, Sekh Thanprasertsuk, Alan Rapoport

    Published 2025-01-01
    “…Understanding the new concept of “Medication Underuse Headache” should encourage the health care provider to consider early intervention with calcitonin gene-related peptide (CGRP) monoclonal antibodies. Galcanezumab given early in the course of the disease, may prevent migraine chronification and have a robust response, moreso than when initiated in later stages of migraine. …”
    Get full text
    Article
  4. 3524

    Occurrence of Taenia species and Toxoplasma gondii in pigs slaughtered in Bujumbura city, Kayanza and Ngozi provinces, Burundi by Salvator Minani, Emma Spiessens, Alyssa Labarrière, Pascal Niyokwizera, Anastasie Gasogo, Jean-Bosco Ntirandekura, Chiara Trevisan, Sarah Gabriël

    Published 2024-12-01
    “…Upon pig slaughter, blood samples were collected to perform indirect ELISA for detecting antibodies against the T. gondii P30 protein in the serum. …”
    Get full text
    Article
  5. 3525

    Autoimmune brainstem encephalitis: Clinical associations, outcomes, and proposed diagnostic criteria by Michael Gilligan, Smathorn Thakolwiboon, Emma Orozco, Samantha Banks, Eoin P. Flanagan, Sebastian Lopez‐Chiriboga, Jan‐Mendelt Tillema, John R. Mills, Sean J. Pittock, Cristina Valencia Sanchez, Anastasia Zekeridou, Divyanshu Dubey, Andrew McKeon

    Published 2025-01-01
    “…Altered mental status (11%) was uncommon. Neural antibodies detected were as follows: KLHL‐11 (26 patients), GAD65 (high titer, 12), ANNA‐1 (anti‐Hu, 8), ANNA‐2 (anti‐Ri, 8), Ma2 (7), IgLON‐5 (6), AQP4 (6), MOG (4), glycine receptor (4), GQ1B (4), PCA‐1 (anti‐Yo, 4), DPPX (2), neurochondrin (2), neurofilament (2), NMDA‐R (2), AGNA‐1 (SOX‐1, 1), ANNA‐3 (DACH1, 1), amphiphysin (1), CRMP‐5 (1), ITPR‐1 (1), PCA‐Tr (DNER, 1), and PDE10A (1). …”
    Get full text
    Article
  6. 3526

    Targets of influenza human T-cell response are mostly conserved in H5N1 by John Sidney, A-Reum Kim, Rory D. de Vries, Bjoern Peters, Philip S. Meade, Florian Krammer, Alba Grifoni, Alessandro Sette

    Published 2025-02-01
    “…Based on these observations, and the overall similarity of the neuraminidase (NA) N1 subtype encoded in both HPAI and seasonal H1N1 influenza virus as well as cross-reactive group 1 HA stalk-reactive antibodies, we expect that a degree of pre-existing immunity is present in the general human population that could blunt the severity of human H5N1 infections.IMPORTANCEInfluenza A viruses (IAVs) cause pandemics that can result in millions of deaths. …”
    Get full text
    Article
  7. 3527

    Prevalence of viral hepatitis B and C infection and associated factors among pregnant women in southeast Ethiopia: community-based crossectional study by Nuruzelam Mohammed, Jeylan Kassim, Ahmednur Adem Aliyi, Muhammed Jemal Abdurebi

    Published 2025-02-01
    “…Data were collected through pretested interviewer administered questionnaire and three milliliter blood sample were collected and tested for HBsAgn and Anti-HCV Antibodies. Descriptive statistics such as frequency, mean, and standard deviation were used to summarize data. …”
    Get full text
    Article
  8. 3528

    Determination of Seroprevalence and Risk Factors of Crimean–Congo Haemorrhagic Fever (CCHF) in the Endemic Region in Turkey: A Population-Based Cross-Sectional Study by Rıza Çıtıl, Mücahit Eğri, Yalçın Önder, Fazilet Duygu, Yunus Emre Bulut, Özkan Yaşayancan, Nagehan Yıldız Çeltek, Şafak Şahin

    Published 2021-01-01
    “…The blood samples were taken, and anti-CCHFV IgG antibodies were measured with ELISA method. Results. 1272 (54.9%) out of 2319 participants were female, and the mean age was 47.3 ± 15.3. …”
    Get full text
    Article
  9. 3529

    Blockade of IL-17A/IL-17R Pathway Protected Mice from Sepsis-Associated Encephalopathy by Inhibition of Microglia Activation by Bo Ye, Tianzhu Tao, Andong Zhao, Liyuan Wen, Xiaofei He, Yi Liu, Qiang Fu, Weidong Mi, Jingsheng Lou

    Published 2019-01-01
    “…On the contrary, neutralizing anti-IL-17A or anti-IL-17R antibodies mitigated the CNS inflammation and microglia activation, thus alleviating the cognitive dysfunction. …”
    Get full text
    Article
  10. 3530

    N-2-Hydroxypropyl Trimethyl Ammonium Chloride Chitosan-Aluminum Nano-Adjuvant Elicit Strong Immune Responses in Porcine Epidemic Diarrhea Inactivated Vaccine by Jin Z, Liu J, Guo S, Xu S, Gong X, Zhang C, Zhao K

    Published 2025-01-01
    “…The levels of PEDV antibodies induced by the N-2-HACC-Al/PEDV were higher than those of commercially available vaccines, both by intramural injection and oral administration. …”
    Get full text
    Article
  11. 3531

    SPA14 liposomes combining saponin with fully synthetic TLR4 agonist provide adjuvanticity to hCMV vaccine candidate by Ernesto Luna, Sophie Ruiz, Marie Garinot, Cyril Chavagnac, Pankaj Agrawal, John Escobar, Laurent Revet, Marie-Jeanne Asensio, Fabienne Piras, Francis G. Fang, Donald R. Drake, Bachra Rokbi, Daniel Larocque, Jean Haensler

    Published 2024-12-01
    “…When tested as an adjuvant in vivo with human cytomegalovirus glycoprotein B (gB) and pentamer complex (PC) as test antigens, SPA14 was generally well tolerated and as active as AS01B for the induction of long-lasting CMV-neutralizing antibodies in mice and non-human primates (NHPs). Both adjuvants promoted the induction of Th-1 responses based on IgG2c production in mice and IFN-γ production in mice and NHPs, but in mice, a higher level of Th-2 cytokines (IL-5) and higher IgG1 over IgG2c secreting cells ratios were obtained with SPA14 indicating that the adjuvant profile of SPA14 could be less Th-1 biased than that of AS01B. …”
    Get full text
    Article
  12. 3532

    STAT4, TRAF3IP2, IL10, and HCP5 Polymorphisms in Sjögren’s Syndrome: Association with Disease Susceptibility and Clinical Aspects by Serena Colafrancesco, Cinzia Ciccacci, Roberta Priori, Andrea Latini, Giovanna Picarelli, Francesca Arienzo, Giuseppe Novelli, Guido Valesini, Carlo Perricone, Paola Borgiani

    Published 2019-01-01
    “…HCP5 rs3099844 was associated with anti-SSA (P=0.006, OR=3.07) and anti-SSB (P=0.005, OR=2.66) antibodies, severity of focus score (P=0.03, OR=12), and lymphoma development (P=0.002, OR=7.23). …”
    Get full text
    Article
  13. 3533

    DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells by Ignacio Melero, Ruth Conde-Garrosa, David Sancho, Santos Mañes, Alfonso R Sanchez-Paulete, Francisco J Cueto, Carlos del Fresno, Paola Brandi, Alexis J. Combes, Elena Hernández-García, Michel Enamorado, Christian P Bromley, Manuel J Gomez, Santiago Zelenay, Salvador Iborra, Matthew F. Krummel

    Published 2021-05-01
    “…Of note, this protection was recapitulated by anti-DNGR-1-blocking antibodies in mice following Flt3L gene therapy. This improved antitumor immunity was associated with Batf3-dependent enhanced accumulation of CD8+ T cells and cDC1s within tumors. …”
    Get full text
    Article
  14. 3534
  15. 3535

    Multicentre adaptive randomised trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin versus calcineurin inhibitor-based or sirolimu... by Simon Gates, Matthew Collin, Victoria Potter, Rebecca Bishop, Ronjon Chakraverty, Kavita Raj, Adrian Bloor, Andrea Hodgkinson, Jeff Davies, Emma Kempshall, Fiona Dignan, Ram Malladi, Siobhan Smith, Charlotte Gaskell, Gabrielle Smith

    Published 2025-01-01
    “…The trial will compare the novel GvHD prophylaxis regimens post-transplant cyclophosphamide (PTCy) in combination with a CNI or sirolimus (PTCy-CNI or PTCy-sirolimus, respectively) to a current standard-of-care GvHD prophylaxis involving the use of Thymoglobulin (a specific brand of ATG containing rabbit polyclonal antibodies). The primary outcome measure is GvHD-free, relapse-free survival at 1 year. …”
    Get full text
    Article
  16. 3536

    Expression and delivery of HA1-M2e antigen using an innovative attenuated Salmonella–mediated delivery system confers promising protection against H9N2 avian influenza challenge by Ram Prasad Aganja, In-Shik Kim, Hyun-Jin Tae, John Hwa Lee

    Published 2025-01-01
    “…Birds immunized with attenuated SG harboring pJHL270 (JOL3025) or pJHL305 (JOL3027) containing HA-M2e showed significant increases in serum IgY and mucosal IgA antibodies, indicating strong humoral and mucosal immune responses, comparable with inactivated commercial vaccine. …”
    Get full text
    Article
  17. 3537

    Cord Direct Antiglobulin Test for Predicting the Need for Phototherapy in Neonates with ABO Incompatibility: A Prospective Cohort Study by Ranjith Balan, Sakthipriya Balaji, Arun Kumar, Subash Sundar, Shrinidhi Krishnan, Ashok Chandrasekaran

    Published 2025-02-01
    “…Introduction: The Direct Antiglobulin Test (DAT) is a screening technique used to detect Immunoglobulin G (IgG) antierythrocyte antibodies on foetal Red Blood Cells (RBCs). Universal bilirubin screening decreases the incidence of severe hyperbilirubinemia. …”
    Get full text
    Article
  18. 3538

    Obesity and fibromyalgia are associated with Difficult-to-Treat Rheumatoid Arthritis (D2T-RA) independent of age and gender by Nicoletta Luciano, Elisa Barone, Enrico Brunetta, Alessio D’Isanto, Maria De Santis, Angela Ceribelli, Marta Caprioli, Giacomo M. Guidelli, Daniela Renna, Carlo Selmi

    Published 2025-01-01
    “…Results Seventy-one/458 (16%) patients fulfilled the 2021 EULAR criteria for D2T-RA with no significant differences for age (median 62 years interquartile range -IQR- 58- 65 vs. 62 IQR 60 – 63 in non-D2T), gender prevalence (23% in both groups) and positivity rates for rheumatoid factors (62% vs. 62% in non-D2T) and Anti-Citrullinated Protein Antibodies (ACPA) (69% vs. 61% in non-D2T). Conversely, D2T-RA cases had significant longer disease duration (median 15 years IQR 13–17 vs. 10 years IQR 9–11 in non-D2T; p < 0.0001). …”
    Get full text
    Article
  19. 3539

    Viral Mimetic Bacterial Outer Membrane Vesicles for Targeting Angiotensin-Converting Enzyme 2 by Ahn G, Yoon HW, Jeong JH, Kim YH, Shin WR, Song MS, Ahn JY

    Published 2025-01-01
    “…As serodiagnostic surrogates, Ag43β 700_RBD OMVs were applied to ACE2 blockade and OMVs-ELISA assay to quantify neutralization antibodies (nAbs). They reduced the robust immune response in vitro, especially IL-6 and IL-1β. …”
    Get full text
    Article
  20. 3540

    Clinical and molecular analysis of JCPyV and BKPyV infection and associated risk of urothelial carcinoma development in the upper tract by Chun-Nun Chao, Chi-Feng Hung, Wei‑Hong Lai, Chun-Liang Tung, Wan-Yun Yeh, Kai-Wu Yang, Meilin Wang, Ya-Yan Lai, Pei-Lain Chen, Cheng-Huang Shen

    Published 2025-02-01
    “…Immunohistochemistry was performed using anti- large T (LT) and anti-p53 monoclonal antibodies to detect the expression of viral early LT protein and cellular p53 protein, respectively. …”
    Get full text
    Article